Zymeworks Inc.(ZYME)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Zymeworks Inc. (ZYME) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZYME at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,926 of 2,960 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (3.5) and profitability (3.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Zymeworks Inc. reports quarterly revenue of $4.6M, net income of $-45.0M, free cash flow of $-31.9M. Top institutional holders of ZYME by reported 13-F value include EcoR1 Capital, Rubric Capital Management, BlackRock, based on the most recent SEC filings. ZYME trades on the Nasdaq exchange and files with the SEC under CIK 1937653. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZYME daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Zymeworks Inc. directly from SEC EDGAR.